Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of “Moderate Buy” from Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $365.40.

A number of equities analysts have recently weighed in on KRYS shares. Weiss Ratings downgraded Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Citigroup lifted their price target on Krystal Biotech from $378.00 to $386.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Wall Street Zen cut Krystal Biotech from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Finally, Royal Bank Of Canada started coverage on Krystal Biotech in a research report on Friday, August 14th. They set an “outperform” rating and a $400.00 target price for the company.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $351.46 on Monday. Krystal Biotech has a fifty-two week low of $136.73 and a fifty-two week high of $382.54. The stock has a market cap of $10.40 billion, a PE ratio of 44.04 and a beta of 0.53. The firm’s 50-day simple moving average is $348.64 and its 200 day simple moving average is $304.16.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million during the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, analysts predict that Krystal Biotech will post 7.48 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total transaction of $347,270.00. Following the completion of the transaction, the executive vice president owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the sale, the director owned 50,000 shares of the company’s stock, valued at $16,456,000. This trade represents a 33.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 51,000 shares of company stock worth $16,278,020. 13.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Large investors have recently modified their holdings of the stock. Corient Private Wealth LP raised its holdings in shares of Krystal Biotech by 767.4% in the 2nd quarter. Corient Private Wealth LP now owns 30,558 shares of the company’s stock worth $11,357,000 after purchasing an additional 27,035 shares during the period. HighTower Advisors LLC lifted its stake in Krystal Biotech by 3.9% in the second quarter. HighTower Advisors LLC now owns 2,129 shares of the company’s stock valued at $791,000 after purchasing an additional 80 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Krystal Biotech during the second quarter valued at $3,865,000. California State Teachers Retirement System grew its holdings in Krystal Biotech by 33,527.2% during the second quarter. California State Teachers Retirement System now owns 8,805,606 shares of the company’s stock valued at $3,272,780,000 after purchasing an additional 8,779,420 shares during the period. Finally, denkapparat Operations GmbH purchased a new stake in Krystal Biotech in the second quarter worth $226,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.